Non-clinical Development Advisory

A strong non-clinical development strategy built with the PMDA’s expectations at its core is critical when it comes to efficient drug development in Japan.

ELIQUENT Japan provides a virtual development team ready to support your non-clinical processes, ensuring your product and regulatory strategy are prepared to advance to clinical study. Here’s how we do it.

Non-clinical know-how for Comprehensive, Strategic Guidance

Once you reach the Non-clinical Development Advisory stage of working with ELIQUENT Japan, we’ve already established a development strategy with precise PMDA consultation results. It’s with these regulatory and development plans in hand that we’ll turn to support your non-clinical study programs and ensure you’re on the pathway to approval in Japan.

Non Clinical Strategic Guidance Img
Non Clinical Support Img

Access strategic, big-picture Non-clinical Support

The experts at ELIQUENT Japan will provide non-clinical development advisory that enables your development approach to succeed at the clinical stage. Our services include:

  • Preparation of a non-clinical trial plan outline.
  • Evaluation and selection of non-clinical testing institutions in Japan and overseas—including conducting GLP facility surveys.
  • Professional review of non-clinical study plans.
  • Management of non-clinical study progress.
  • Strategic advice for non-clinical testing institutions.
  • Comprehensive review of non-clinical study reports.

Non-clinical Development Advisory that sets the stage for your clinical study in Japan.

ELIQUENT Japan is here to help.

Learn more about how ELIQUENT Japan can serve you.

Kol Management Icon

KOL Management

Learn More

Market Entry Planning Icon

Market Entry Planning

Learn More

Clinical Development Advisory Icon

Clinical Development Advisory

Learn More

Are you ready to streamline your entry into Japan with ELIQUENT Japan?